Samsung Biologics showcased its exhibition booth at the Bio International Convention in San Diego, where an alliance comprising South Korea, the United States, Japan, India, and the European Union was unveiled. This alliance is focused on working together to establish a robust and resilient supply chain within the biopharmaceutical sector. The inaugural meeting of the Biopharmaceutical Alliance took place at the Bio International Convention 2024, bringing together government officials and industry representatives from the participating countries. Key themes of the meeting included the significance of a dependable supply chain, coordination of bio policies and regulations, and collaborative efforts to address production shortages experienced during the COVID-19 pandemic. The alliance was formed in response to the challenges faced in drug supply chains during the pandemic. Initially initiated by South Korea and the US during discussions on core emerging technologies, the alliance was later expanded to include Japan, India, and the EU. The participants acknowledged the need to address the concentration of essential raw material and ingredient production in a limited number of countries, and are committed to developing a detailed pharmaceutical supply chain map as part of their collaborative efforts.